Spots Global Cancer Trial Database for recurrent breast cancer
Every month we try and update this database with for recurrent breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00075764 | Breast Cancer | anastrozole fulvestrant | 18 Years - | SWOG Cancer Research Network | |
| Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery | NCT00381901 | Breast Cancer | trastuzumab polymorphism an... adjuvant therap... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer | NCT00238290 | Breast Cancer | Trastuzumab + L... | 18 Years - 120 Years | Swiss Group for Clinical Cancer Research | |
| A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | NCT01824836 | Estrogen Recept... Musculoskeletal... Progesterone Re... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | anastrozole questionnaire a... laboratory biom... pharmacogenomic... | 18 Years - | Eastern Cooperative Oncology Group | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Chemotherapy in Treating Patients With Breast Cancer | NCT00012129 | Breast Cancer | liposomal annam... | 18 Years - 120 Years | NYU Langone Health | |
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | NCT00471432 | Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu... | custirsen sodiu... docetaxel pharmacological... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | NCT00688194 | Breast Cancer | anastrozole exemestane fulvestrant lapatinib ditos... letrozole placebo | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00006104 | Breast Cancer | trastuzumab docetaxel | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy | NCT01487954 | Radiation Toxic... Recurrent Breas... Stage I Breast ... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | alkaline water distilled water external beam r... | 18 Years - | Case Comprehensive Cancer Center | |
| Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus | NCT02015559 | Estrogen Recept... HER2-negative B... Oral Complicati... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | mucoadhesive or... laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer | NCT00003536 | Stage IV Breast... Recurrent Breas... | antineoplaston ... methotrexate alternative pro... biological ther... biologically ba... cancer preventi... chemotherapy complementary a... differentiation... | - | National Cancer Institute (NCI) | |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | NCT00003440 | HER2-negative B... HER2-positive B... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel trastuzumab quality-of-life... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Doxorubicin in Treating Women With Advanced Breast Cancer | NCT00003165 | Breast Cancer | doxorubicin-HPM... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer | NCT00003066 | Breast Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function | NCT00002901 | Breast Cancer Head and Neck C... Lung Cancer Ovarian Cancer Unspecified Adu... | docetaxel | 18 Years - | City of Hope Medical Center | |
| Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer | NCT00039520 | Breast Cancer | docetaxel sulindac | 18 Years - | Fox Chase Cancer Center | |
| Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery | NCT00305825 | Breast Cancer | bevacizumab letrozole | 18 Years - 120 Years | University of California, San Francisco | |
| Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer | NCT00751101 | Breast Cancer Chemotherapeuti... Palmar-plantar ... | Nicotine patch | 18 Years - 75 Years | University of California, San Francisco | |
| Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer | NCT00020176 | Breast Cancer | filgrastim therapeutic all... cyclophosphamid... cyclosporine fludarabine pho... peripheral bloo... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu | NCT00085020 | Breast Cancer | trastuzumab lapatinib ditos... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer | NCT00337233 | Breast Cancer Fatigue Ovarian Cancer Psychosocial Ef... | yoga therapy | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer | NCT00002866 | Breast Cancer Neutropenia | filgrastim docetaxel epirubicin hydr... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer | NCT00006459 | Breast Cancer | gemcitabine hyd... paclitaxel | 18 Years - | Eli Lilly and Company | |
| High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer | NCT00003068 | Breast Cancer Drug/Agent Toxi... | amifostine trih... cyclophosphamid... mitoxantrone hy... thiotepa peripheral bloo... | 16 Years - 70 Years | National Cancer Institute (NCI) | |
| ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00404404 | Breast Cancer | bevacizumab paclitaxel albu... | 18 Years - | National Cancer Institute (NCI) | |
| SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer | NCT00005822 | Breast Cancer | doxorubicin hyd... semaxanib conventional su... radiation thera... tamoxifen | 18 Years - | Case Comprehensive Cancer Center | |
| Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer | NCT01706432 | Central Nervous... Invasive Ductal... Invasive Ductal... Invasive Lobula... Invasive Lobula... Liver Metastase... Lobular Breast ... Lung Metastases Male Breast Can... Medullary Ducta... Mucinous Ductal... Papillary Ducta... Recurrent Breas... Stage IV Breast... Tubular Ductal ... Tumors Metastat... | hyperfractionat... laboratory biom... stereotactic ra... | 18 Years - | University of Chicago | |
| Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00006104 | Breast Cancer | trastuzumab docetaxel | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer | NCT00404404 | Breast Cancer | bevacizumab paclitaxel albu... | 18 Years - | National Cancer Institute (NCI) | |
| Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics | NCT00656604 | Breast Cancer | proteomic profi... lumpectomy or m... dynamic contras... histopathologic... magnetic resona... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery | NCT00381901 | Breast Cancer | trastuzumab polymorphism an... adjuvant therap... | 18 Years - | National Cancer Institute (NCI) | |
| Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel | NCT01050075 | Breast Cancer Stage I Breast ... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | acupuncture the... questionnaire a... management of t... | 18 Years - | City of Hope Medical Center | |
| Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions | NCT00471601 | Breast Cancer | counseling inte... questionnaire a... psychosocial as... quality-of-life... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone | NCT00301886 | Breast Cancer Hypercalcemia o... Metastatic Canc... Pain | ibandronate zoledronate quality-of-life... | 18 Years - | SWOG Cancer Research Network | |
| Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer | NCT00346229 | Breast Cancer | filgrastim pegfilgrastim lyso-thermosens... hyperthermia tr... | 18 Years - | Duke University | |
| Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer | NCT00002680 | Breast Cancer | filgrastim cyclophosphamid... megestrol aceta... melphalan tamoxifen citra... thiotepa conventional su... peripheral bloo... radiation thera... | 18 Years - | Yale University | |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | NCT00003440 | HER2-negative B... HER2-positive B... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel trastuzumab quality-of-life... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 | NCT00005635 | Breast Cancer | trastuzumab paclitaxel | 18 Years - | Genentech, Inc. | |
| Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer | NCT01385280 | Estrogen Recept... Progesterone Re... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | therapeutic est... exemestane laboratory biom... enzyme-linked i... | - | University of Arizona | |
| Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer | NCT00003135 | Breast Cancer Cervical Cancer Endometrial Can... Ovarian Cancer | fluorouracil pegylated lipos... hyperthermia tr... | 18 Years - | National Cancer Institute (NCI) | |
| Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer | NCT00503906 | Breast Cancer | Avastin Gemcitabine Abraxane | 18 Years - 120 Years | University of Miami | |
| Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions | NCT00471601 | Breast Cancer | counseling inte... questionnaire a... psychosocial as... quality-of-life... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer | NCT00303992 | Breast Cancer | trastuzumab irinotecan hydr... | - 120 Years | University of California, San Francisco | |
| Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | NCT00004013 | Breast Cancer | trastuzumab paclitaxel | - | Fred Hutchinson Cancer Center | |
| Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | NCT01233505 | Adenocarcinoma ... Adenocarcinoma ... BRCA1 Mutation ... BRCA2 Mutation ... Ovarian Mucinou... Recurrent Breas... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Colon ... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Rectal... Unspecified Adu... | veliparib capecitabine oxaliplatin pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer | NCT01009983 | Breast Cancer Recurrent Breas... Stage IV Breast... | panitumumab paclitaxel carboplatin laboratory biom... immunohistochem... | 18 Years - | Wake Forest University Health Sciences | |
| DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer | NCT00899548 | Breast Cancer | DNA methylation... microarray anal... polymerase chai... laboratory biom... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer | NCT00376805 | Breast Cancer | Fludarabine Cyclophosphamid... Total body irra... Natural killer ... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | NCT06202261 | Metastatic Brea... Recurrent Breas... Advanced Malign... | TQB2930 for inj... Paclitaxel for ... TQB3616 capsule Fulvestrant inj... Capecitabine ta... Vinorelbine tar... Eribulin mesyla... gemcitabine hyd... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer | NCT00362973 | Breast Cancer | laboratory biom... needle biopsy positron emissi... radionuclide im... fludeoxyglucose... | 18 Years - 120 Years | University of Washington | |
| A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | NCT06075810 | Breast Cancer Breast Neoplasm Breast Cancer S... | MBQ-167 | 21 Years - | MBQ Pharma | |
| St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer | NCT00110136 | Breast Cancer Hot Flashes | St. John's Wort | 18 Years - | Wake Forest University Health Sciences | |
| LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer | NCT00006007 | Breast Cancer | gemcitabine hyd... pemetrexed diso... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer | NCT00054275 | Breast Cancer | docetaxel erlotinib hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer | NCT00028483 | Breast Cancer | cBR96-doxorubic... docetaxel | 18 Years - | Seagen Inc. | |
| Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer | NCT00006120 | Breast Cancer | docetaxel paclitaxel | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00266110 | Breast Cancer | sargramostim therapeutic aut... trastuzumab vinorelbine dit... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer | NCT00489125 | Breast Cancer | physiologic tes... | - 120 Years | Wake Forest University Health Sciences | |
| Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer | NCT00004013 | Breast Cancer | trastuzumab paclitaxel | - | Fred Hutchinson Cancer Center | |
| Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer | NCT00054145 | Breast Cancer | perifosine | 18 Years - | University Health Network, Toronto | |
| Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer | NCT00075413 | Breast Cancer | arsenic trioxid... | 18 Years - 120 Years | The University of Texas Medical Branch, Galveston | |
| Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | NCT01705340 | Adenocarcinoma ... HER2-positive B... Male Breast Can... Recurrent Breas... Recurrent Esoph... Recurrent Gastr... Stage IIIC Brea... Stage IIIC Esop... Stage IIIC Gast... Stage IV Breast... Stage IV Esopha... Stage IV Gastri... | Akt inhibitor M... trastuzumab lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients. | NCT06202118 | Breast Cancer Recurrent Breas... Breast Carcinom... | Diffusing Alpha... | 65 Years - 120 Years | Alpha Tau Medical LTD. | |
| Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer | NCT00066378 | Breast Cancer | anastrozole gefitinib | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer | NCT00424164 | Breast Cancer | lapatinib ditos... tamoxifen citra... pharmacological... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer | NCT00379509 | Breast Cancer | lapatinib ditos... TdT-mediated dU... gene expression... microarray anal... immunohistochem... biopsy radiation thera... | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | NCT01938833 | HER2-negative B... Inflammatory Br... Male Breast Can... Recurrent Breas... Stage IV Breast... | Romidepsin Abraxane | 18 Years - | Thomas Jefferson University | |
| 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer | NCT00095888 | Male Breast Can... Recurrent Breas... Stage IV Breast... | triapine gemcitabine hyd... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | NCT00834678 | Breast Cancer | bendamustine erlotinib Maintenance erl... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery | NCT01292083 | Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Triple-negative... | azacitidine laboratory biom... immunohistochem... polymerase chai... western blottin... nucleic acid se... therapeutic con... | 18 Years - | University of Southern California | |
| A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases | NCT01939483 | Central Nervous... Male Breast Can... Recurrent Breas... Stage IV Breast... | irinotecan hydr... laboratory biom... | 18 Years - | University of California, Irvine | |
| Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer | NCT00086957 | Breast Cancer | trastuzumab docetaxel gefitinib | 18 Years - | City of Hope Medical Center | |
| Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer | NCT02060253 | HER2-positive B... Male Breast Can... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | ganetespib paclitaxel trastuzumab pertuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer | NCT00079157 | Breast Cancer | incomplete Freu... sargramostim telomerase: 540... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | NCT03315364 | Recurrent or Me... | Oral paclitaxel Paclitaxel inje... | 19 Years - | Daehwa Pharmaceutical Co., Ltd. | |
| Acupuncture in Treating Hot Flashes in Women With Breast Cancer | NCT00081965 | Breast Cancer Hot Flashes | acupuncture the... hot flashes att... management of t... | - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
